|Age:||18 years or older|
|Keywords:||Diabetic Macular Edema, macular edema|
|Type:||Drug study, Phase 3|
The purpose of this study is to find out if starting with Eylea has better results than starting with the less expensive drug, Avastin, and only switching to Eylea if needed. If starting with Eylea is not better than starting with Avastin and switching to Eylea if needed, the potential cost savings to future patients and the health care system would be substantial. However, if starting with Eylea is better, then patients, clinicians, and health care providers can make informed decisions for how to best treat patients with DME and at least moderate vision loss.
If you agree to take part in the study, you will have a 50:50 chance of receiving Eylea from the start or receiving Avastin to start and switching to Eylea only if needed. If you start with Avastin, you initially will get an injection once a month for 3 months. At 3 months or anytime thereafter, if there has not been enough improvement in your vision and DME, you will be switched to Eylea. We expect about half of the eyes to switch to Eylea during the study. The entire study will last 2 years.
To summarize, both Eylea and Avastin have been shown to work for DME treatment. However, in patients with vision and DME like yours, Eylea has been shown to work better on average. It is possible that starting with Eylea will have similar results to starting with Avastin and switching to Eylea only if needed. By doing this study, we hope to be able to provide additional information for people with DME on how these two approaches compare.
To be eligible, the following inclusion criteria must be met:
An individual is not eligible if any of the following exclusion criteria are present:
Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.